JFL Life Sciences Ltd is a manufacturer of pharmaceutical products. The company, founded in 2010 under the name JFL Life Sciences Private Limited, has its registered office in Ahmedabad, Gujarat. The company had its initial public offering in 2022 and got certified with the name JFL Life Sciences Ltd. As of November 25, 2022, the company has a market capitalisation of Rs 43.72 crore.
In the last quarter of 2021, JFL Life Sciences Ltd earned Rs 25.63 crore in revenue and made a profit of Rs 2.53 crore after tax. The profit in the first quarter of 2021 was Rs 0.54 crore.
JFL Life Sciences Ltd. had its IPO between August 25 and August 30, 2022. The face value was Rs 10, the share price was Rs 61, and the lot size was 2,000 shares. The company was listed on the National Stock Exchange on September 8, 2022, with the ticker JFLLIFE.
JFL Life Sciences Ltd. is a pharmaceutical company with an impressive line of products and manufacturing facilities. The company is active in India and 10 other developed and developing countries. JFL Life Sciences Ltd. engages in bulk sales of products to pharmaceutical marketers and traders, who in turn provide them with the channels to sell to the customers. The company does not sell under any specific brand name. Its product portfolio includes dry powder injections, tablets and capsules (B-Lactam) solid oral dosage form, tablets and capsules (General), and Oral Rehydration Solutions (ORS).
Smiral Ashwinkumar Patel is the chairman and managing director of the company. Tejas Smiral Patel is the whole-time director, Manishkumar Jasavantlal Patel is the non-executive director, and Bhavna Shah is an independent director.
On November 25, 2022, JFL Life Sciences share price closed at Rs 39.75. The company’s share prices have gone down by 40.23% since its listing on the NSE on September 8, 2022. The peak share price was Rs 66.50, and the lowest was Rs 39. The share prices have gone down by 13.49% in the past month.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: email@example.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.